Aclaris Therapeutics (ACRS) Change in Acquisitions & Divestments (2014 - 2026)

Aclaris Therapeutics' Change in Acquisitions & Divestments history runs 13 years deep, the most recent figure standing at $20.8 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 30.81% year-over-year to $20.8 million in Q1 2026; TTM through Mar 2026 was $79.8 million, a 19.53% decrease from a year earlier, with the FY2025 full-year figure at $89.0 million, up 3.36% from the prior year.
• Change in Acquisitions & Divestments climbed to $20.8 million in Q1 2026 per ACRS's latest filing, from $15.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $70.6 million in Q2 2023 and bottomed at $8.0 million in Q4 2023.
• The 5-year median for Change in Acquisitions & Divestments is $30.0 million (2025), against an average of $32.8 million.
• Across the five-year window, Change in Acquisitions & Divestments soared 325.28% in 2022 and tumbled 83.64% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $48.8 million in 2022, then tumbled by 83.64% to $8.0 million in 2023, then surged by 119.17% to $17.5 million in 2024, then decreased by 14.35% to $15.0 million in 2025, then soared by 38.32% to $20.8 million in 2026.
• Per Business Quant, the three latest ACRS Change in Acquisitions & Divestments figures stand at $20.8 million (Q1 2026), $15.0 million (Q4 2025), and $19.1 million (Q3 2025).